Skip to main content
Erschienen in: The Patient - Patient-Centered Outcomes Research 4/2011

01.12.2011 | Original Research Article

Estimation of Utilities in Attention-Deficit Hyperactivity Disorder for Economic Evaluations

verfasst von: Dr Andrew Lloyd, Paul Hodgkins, Rahul Sasane, Ron Akehurst, Edmund J.S. Sonuga-Barke, Patrick Fitzgerald, Annabel Nixon, Haim Erder, John Brazier

Erschienen in: The Patient - Patient-Centered Outcomes Research | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Background: Attempts to estimate the cost effectiveness of attention-deficit hyperactivity disorder (ADHD) treatments in the past have relied on classifying ADHD patients as responders or non-responders to treatment. Responder status has been associated with a small gain in health-related quality of life (HR-QOL) [or utility, as measured using the generic QOL measure EQ-5D] of 0.06 (on a scale from 0 being dead to 1.0 being full health).
Objectives: The goal of the present study was to develop and validate several ADHD-related health states, and to estimate utility values measured amongst the general public for those states and to re-estimate utility values associated with responder status.
Methods: Detailed qualitative interview data were collected from 20 young ADHD patients to characterize their HR-QOL. In addition, item-by-item clinical and HR-QOL data from a clinical trial were used to define and describe four health states (normal; borderline to mildly ill; moderately to markedly ill; and severely ill). ADHD experts assessed the content validity of the descriptions. The states were rated by 100 members of the UK general public using the time trade-off (TTO) interview and visual analog scale. Statistical mapping was also undertaken to estimate Clinical Global Impression-Improvement (CGI-I) utilities (i.e. response status) from Clinical Global Impression-Severity (CGI-S) defined states. The mapping work estimated changes in utilities from study baseline to last visit for patients with a CGI-I score of ≤2 or ≤3.
Results: The validity of the four health states developed in this study was supported by in-depth interviews with ADHD experts and patients, and clinical trial data. TTO-derived utilities for the four health states ranged from 0.839 (CGI-S state ‘normal’) to 0.444 (CGI-S state ‘severely ill’). From the mapping work, the change in utility for treatment responders was 0.19 for patients with a CGI-I score of ≤2 and 0.15 for patients with a CGI-I score of ≤3.
Conclusions: The present study provides utilities for different severity levels of ADHD estimated in a TTO study. This approach provides a more granular assessment of the impact of ADHD on HR-QOL than binary approaches employed in previous economic analyses. Change in utility for responders and non-responders at different levels of CGI-I was estimated, and thus these utilities may be used to compare health gains of different ADHD interventions.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: APA, 1994 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: APA, 1994
2.
Zurück zum Zitat National Institute for Health and Clinical Excellence. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. (TA98). London: NICE, 2006 Mar [online]. Available from URL: http://www.nice.org.uk/TA098 [Accessed 2009 May 6] National Institute for Health and Clinical Excellence. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. (TA98). London: NICE, 2006 Mar [online]. Available from URL: http://​www.​nice.​org.​uk/​TA098 [Accessed 2009 May 6]
3.
Zurück zum Zitat Pliszka SR, Carlson C, Swanson JM. ADHD with comorbid disorders: clinical assessment and management. New York: Guilford, 1999 Pliszka SR, Carlson C, Swanson JM. ADHD with comorbid disorders: clinical assessment and management. New York: Guilford, 1999
4.
Zurück zum Zitat Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child 2005; 90: 2–7CrossRef Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child 2005; 90: 2–7CrossRef
5.
Zurück zum Zitat Biederman J, Newcom J, Sprich S. Comorbidity of attention-deficit hyperactivity disorder with conduct, depressive, anxiety and other disorders. Am J Psychiatry 1991; 148: 564–77PubMed Biederman J, Newcom J, Sprich S. Comorbidity of attention-deficit hyperactivity disorder with conduct, depressive, anxiety and other disorders. Am J Psychiatry 1991; 148: 564–77PubMed
6.
Zurück zum Zitat Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective. J Dev Behav Pediatr 2007; 28: 265–73PubMedCrossRef Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective. J Dev Behav Pediatr 2007; 28: 265–73PubMedCrossRef
7.
Zurück zum Zitat Kendall J, Hatton D, Beckett A, et al. Children’s accounts of attention-deficit/hyperactivity disorder. Adv Nurs Science 2003; 26: 114–30 Kendall J, Hatton D, Beckett A, et al. Children’s accounts of attention-deficit/hyperactivity disorder. Adv Nurs Science 2003; 26: 114–30
8.
Zurück zum Zitat Schatz DB, Rostain AL. ADHD with comorbid anxiety: a review of the current literature. J Atten Disord 2006; 10: 141–9PubMedCrossRef Schatz DB, Rostain AL. ADHD with comorbid anxiety: a review of the current literature. J Atten Disord 2006; 10: 141–9PubMedCrossRef
9.
Zurück zum Zitat Levy F. Synaptic gating and ADHD: a biological theory of comorbidity of ADHD and anxiety. Neuropsychopharmacology 2004; 29: 1589–96PubMedCrossRef Levy F. Synaptic gating and ADHD: a biological theory of comorbidity of ADHD and anxiety. Neuropsychopharmacology 2004; 29: 1589–96PubMedCrossRef
10.
Zurück zum Zitat Treuting JJ, Hinshaw SP. Depression and self-esteem in boys with attention-deficit/hyperactivity disorder: associations with comorbid aggression and explanatory attribution mechanisms. J Abnorm Child Psychol 2001; 29: 23–39PubMedCrossRef Treuting JJ, Hinshaw SP. Depression and self-esteem in boys with attention-deficit/hyperactivity disorder: associations with comorbid aggression and explanatory attribution mechanisms. J Abnorm Child Psychol 2001; 29: 23–39PubMedCrossRef
11.
Zurück zum Zitat Ralston SJ, Lorenzo MJM. ADORE — Attention-Deficit hyperactivity disorder Observational Research in Europe. Eur Child Adolesc Psychiatry 2004; 13 (1 Suppl.): i36–42PubMedCrossRef Ralston SJ, Lorenzo MJM. ADORE — Attention-Deficit hyperactivity disorder Observational Research in Europe. Eur Child Adolesc Psychiatry 2004; 13 (1 Suppl.): i36–42PubMedCrossRef
12.
Zurück zum Zitat Nijmeijer JS, Minderaa RB, Buitelaar JK, et al. Attention-deficit/hyperactivity disorder and social dysfunctioning. Clin Psychol Rev 2008; 28: 692–708PubMedCrossRef Nijmeijer JS, Minderaa RB, Buitelaar JK, et al. Attention-deficit/hyperactivity disorder and social dysfunctioning. Clin Psychol Rev 2008; 28: 692–708PubMedCrossRef
13.
Zurück zum Zitat Coghill D, Danckaerts M, Sonuga-Barke E, et al. Practitioner review: quality of life in child mental health — conceptual challenges and practical choices. J Child Psychol Psychiatry 2009; 50(5): 544–61PubMedCrossRef Coghill D, Danckaerts M, Sonuga-Barke E, et al. Practitioner review: quality of life in child mental health — conceptual challenges and practical choices. J Child Psychol Psychiatry 2009; 50(5): 544–61PubMedCrossRef
14.
Zurück zum Zitat Klassen AF, Miller A, Fine S. Agreement between parent and child report of quality of life in children with attentiondeficit/hyperactivity disorder. Child Care Health Dev 2006; 32: 397–406PubMedCrossRef Klassen AF, Miller A, Fine S. Agreement between parent and child report of quality of life in children with attentiondeficit/hyperactivity disorder. Child Care Health Dev 2006; 32: 397–406PubMedCrossRef
15.
Zurück zum Zitat Escobar R, Soutullo CA, Hervas A, et al. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 2005; 116(3): e364–9PubMedCrossRef Escobar R, Soutullo CA, Hervas A, et al. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 2005; 116(3): e364–9PubMedCrossRef
16.
Zurück zum Zitat Topolski TD, Edwards DC, Patrick DL, et al. Quality of life of adolescent males with attention-deficit hyperactivity disorder. J Atten Disord 2004; 7: 163–73PubMedCrossRef Topolski TD, Edwards DC, Patrick DL, et al. Quality of life of adolescent males with attention-deficit hyperactivity disorder. J Atten Disord 2004; 7: 163–73PubMedCrossRef
17.
Zurück zum Zitat Buitelaar JK, Wilens TE, Zhang S, et al. Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo. J Child Psychol Psychiatry 2009; 50: 335–42PubMedCrossRef Buitelaar JK, Wilens TE, Zhang S, et al. Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo. J Child Psychol Psychiatry 2009; 50: 335–42PubMedCrossRef
18.
Zurück zum Zitat Bukstein OG, Arnold LE, Landgraf JM, et al. Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder? Child Adolesc Psychiatry Ment Health 2009; 3(1): 39PubMedCrossRef Bukstein OG, Arnold LE, Landgraf JM, et al. Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder? Child Adolesc Psychiatry Ment Health 2009; 3(1): 39PubMedCrossRef
19.
Zurück zum Zitat Manos M, Frazier TW, Landgraf JM, et al. HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system. Curr Med Res Opin 2009; 25(12): 3001–10PubMedCrossRef Manos M, Frazier TW, Landgraf JM, et al. HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system. Curr Med Res Opin 2009; 25(12): 3001–10PubMedCrossRef
20.
Zurück zum Zitat Landgraf JM, Rich M, Rappaport L. Measuring quality of life in children with attention-deficit hyperactivity disorder and their families. Arch Pediatr Adolesc Med 2002; 156:384–91PubMed Landgraf JM, Rich M, Rappaport L. Measuring quality of life in children with attention-deficit hyperactivity disorder and their families. Arch Pediatr Adolesc Med 2002; 156:384–91PubMed
21.
Zurück zum Zitat Meaux JB, Hester C, Smith B, et al. Stimulant medications: a trade-off? The lived experience of adolescents with ADHD. J Spec Pediatr Nurs 2006; 11: 214–26PubMedCrossRef Meaux JB, Hester C, Smith B, et al. Stimulant medications: a trade-off? The lived experience of adolescents with ADHD. J Spec Pediatr Nurs 2006; 11: 214–26PubMedCrossRef
22.
Zurück zum Zitat National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008 June [online]. Available from URL: http://www.nice. org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008. pdf [Accessed 2009 May 6] National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008 June [online]. Available from URL: http://​www.​nice.​ org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008. pdf [Accessed 2009 May 6]
23.
Zurück zum Zitat Coghill D, Spender Q, Barton J, et al. Measuring quality of life in children with attention-deficit-hyperactivity disorder in the United Kingdom. 16th World Congress of the International Association of Child and Adolescent Psychiatry and Allied Professions (IACAPAP); 2004 Aug 23–26; Berlin Coghill D, Spender Q, Barton J, et al. Measuring quality of life in children with attention-deficit-hyperactivity disorder in the United Kingdom. 16th World Congress of the International Association of Child and Adolescent Psychiatry and Allied Professions (IACAPAP); 2004 Aug 23–26; Berlin
24.
Zurück zum Zitat Joffe H, Yardley L. Content and thematic analysis. In: Marks D, Yardley L, editors. Research methods for clinical and health psychology. London: Sage, 2004: 56–68 Joffe H, Yardley L. Content and thematic analysis. In: Marks D, Yardley L, editors. Research methods for clinical and health psychology. London: Sage, 2004: 56–68
25.
Zurück zum Zitat Arnold LE, Bozzolo DR, Hodgkins P, et al. Switching from oral extended-release methylphenidate to the methylphenidate transdermal system: continued attention-deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Curr Med Res Opin 2010; 26: 129–37PubMedCrossRef Arnold LE, Bozzolo DR, Hodgkins P, et al. Switching from oral extended-release methylphenidate to the methylphenidate transdermal system: continued attention-deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Curr Med Res Opin 2010; 26: 129–37PubMedCrossRef
26.
Zurück zum Zitat Guy W. ECDEU assessment manual for psychopharmacology. Rockville (MD): US Department of Health, Education, and Welfare, 1976: 218-22. DHEW publication no.: ADM 76-338 Guy W. ECDEU assessment manual for psychopharmacology. Rockville (MD): US Department of Health, Education, and Welfare, 1976: 218-22. DHEW publication no.: ADM 76-338
27.
Zurück zum Zitat DuPaul GJ, Reid R, Power TJ, et al. ADHD rating scale -IV: checklists, norms, and clinical interpretation. New York: Guildford Publications, 1998 DuPaul GJ, Reid R, Power TJ, et al. ADHD rating scale -IV: checklists, norms, and clinical interpretation. New York: Guildford Publications, 1998
28.
Zurück zum Zitat Bennett KJ, Torrance GW. Measuring health status preferences and utilities: rating scale, time trade-off, and standard gamble techniques. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1996: 575–86 Bennett KJ, Torrance GW. Measuring health status preferences and utilities: rating scale, time trade-off, and standard gamble techniques. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1996: 575–86
29.
Zurück zum Zitat Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986; 5: 1–30PubMedCrossRef Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986; 5: 1–30PubMedCrossRef
30.
Zurück zum Zitat McGough JJ, Wigal SB, Abikoff J, et al. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord 2006; 9: 476–85PubMedCrossRef McGough JJ, Wigal SB, Abikoff J, et al. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord 2006; 9: 476–85PubMedCrossRef
31.
Zurück zum Zitat Conners KC. Conners’ rating scales — revised: technical manual. North Tonawanda, NY: Multi-Health Systems Inc., 2007 Conners KC. Conners’ rating scales — revised: technical manual. North Tonawanda, NY: Multi-Health Systems Inc., 2007
32.
Zurück zum Zitat Lloyd AJ, van Hanswijck de Jonge P, Doyle S, et al. Health state utility scores for cancer-related anaemia through societal and patient valuations. Value Health 2008; 11(7): 1178–85PubMedCrossRef Lloyd AJ, van Hanswijck de Jonge P, Doyle S, et al. Health state utility scores for cancer-related anaemia through societal and patient valuations. Value Health 2008; 11(7): 1178–85PubMedCrossRef
33.
Zurück zum Zitat Kind P, Dolan P, Gudex C, et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998; 316: 736–41PubMedCrossRef Kind P, Dolan P, Gudex C, et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998; 316: 736–41PubMedCrossRef
34.
Zurück zum Zitat Matza LS, Secnik K, Rentz AM, et al. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report. Qual Life Res 2005; 14: 735–47PubMed Matza LS, Secnik K, Rentz AM, et al. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report. Qual Life Res 2005; 14: 735–47PubMed
35.
Zurück zum Zitat Kostopoulou O. The transient nature of utilities and health preferences. Med Decis Making 2006; 26: 304–6PubMedCrossRef Kostopoulou O. The transient nature of utilities and health preferences. Med Decis Making 2006; 26: 304–6PubMedCrossRef
Metadaten
Titel
Estimation of Utilities in Attention-Deficit Hyperactivity Disorder for Economic Evaluations
verfasst von
Dr Andrew Lloyd
Paul Hodgkins
Rahul Sasane
Ron Akehurst
Edmund J.S. Sonuga-Barke
Patrick Fitzgerald
Annabel Nixon
Haim Erder
John Brazier
Publikationsdatum
01.12.2011
Verlag
Springer International Publishing
Erschienen in
The Patient - Patient-Centered Outcomes Research / Ausgabe 4/2011
Print ISSN: 1178-1653
Elektronische ISSN: 1178-1661
DOI
https://doi.org/10.2165/11592150-000000000-00000

Weitere Artikel der Ausgabe 4/2011

The Patient - Patient-Centered Outcomes Research 4/2011 Zur Ausgabe

Acknowledgments

Acknowledgment